{'fraction_non_alphanumeric': 0.03155006858710562, 'fraction_numerical': 0.012345679012345678, 'mean_word_length': 5.3478260869565215, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Interference of daratumumab with compatibility testing in blood bank

Plasma cell myeloma accounts for 1% of malignant tumors and 10%–15% of hematopoietic neoplasms. Daratumumab (DARA), a novel targeted immunotherapy drug, was approved by the Food and Drug Administration to treat relapsed/refractory multiple myeloma. DARA, which is a CD38-targeted immunomodulatory drug, also cross-reacts with red cells and sensitizes them, causing difficulties and delay in the blood bank. To avoid delay in view of patient care, proper communication with blood bank professionals is required. We present a case of relapsed/refractory multiple myeloma in a 45-year-old male who required transfusions due to anemia and severe thrombocytopenia.